source
- Biossil Labs acquires Theriva's antibiotic-degrader portfolio in up to $91 million dealBiossil Labs, a Canadian biotech backed by OpenAI, announced a deal to acquire Theriva Biologics' early- to mid-stage portfolio of antibiotic‑degrading enzymes for a total potential value of up to…
- FDA places partial hold on Bright Minds' seizure trial over mouse toxicity concernsThe FDA issued a partial clinical hold on Bright Minds Biosciences' planned phase 2 trial of BMB-101 in patients with developmental and epileptic encephalopathies. The hold was triggered by precli…